Drug intelligence / Profile preview

RAB-002

Development stage: Preclinical
Lead developer: Zhongshan Laibo Ruichen Biopharmaceutical
Modality: Peptides
Administration: Subcutaneous, Local

Overview

RAB-002 is a peptide-based therapeutic candidate being developed by ZhongShan LaiBo RuiChen BioMedicine (RabPharma) for the treatment of osteoporosis and bone fractures. Currently in the preclinical stage, the drug is designed for subcutaneous or local administration. While specific molecular targets or mechanisms of action have not been publicly disclosed by the developer, the peptide modality suggests a targeted approach to bone health, potentially involving the regulation of bone formation or resorption pathways. It is part of a specialized pipeline focused on bone and joint health diseases.

Beyond the preview

Go deeper on RAB-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAB-002.

Explore the full profile